CompletedPHASE1, PHASE2NCT00305864
Motexafin Gadolinium, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme or Gliosarcoma
Studying Gliosarcoma
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- National Cancer Institute (NCI)
- Principal Investigator
- David Brachman, MDRadiation Therapy Oncology Group
- Intervention
- 3-Dimensional Conformal Radiation Therapy(radiation)
- Enrollment
- 118 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2006 – 2011
Study locations (30)
- Mobile Infirmary Medical Center, Mobile, Alabama, United States
- Arizona Oncology Services Foundation, Scottsdale, Arizona, United States
- The University of Arizona Medical Center-University Campus, Tucson, Arizona, United States
- East Bay Radiation Oncology Center, Castro Valley, California, United States
- Eden Hospital Medical Center, Castro Valley, California, United States
- Valley Medical Oncology Consultants-Castro Valley, Castro Valley, California, United States
- Bay Area Breast Surgeons Inc, Emeryville, California, United States
- Valley Medical Oncology Consultants-Fremont, Fremont, California, United States
- Saint Rose Hospital, Hayward, California, United States
- Los Angeles County-USC Medical Center, Los Angeles, California, United States
- USC / Norris Comprehensive Cancer Center, Los Angeles, California, United States
- Contra Costa Regional Medical Center, Martinez, California, United States
- El Camino Hospital, Mountain View, California, United States
- Highland General Hospital, Oakland, California, United States
- Alta Bates Summit Medical Center - Summit Campus, Oakland, California, United States
- +15 more locations on ClinicalTrials.gov
Collaborators
Radiation Therapy Oncology Group
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT00305864 on ClinicalTrials.govOther trials for Gliosarcoma
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE2NCT07301268GI-102 Alone or With Pembrolizumab Before Surgery for Treatment of Recurrent or Progressive IDH Wildtype Glioblastoma and IDH Mutated Grade 4 AstrocytomaMayo Clinic
- RECRUITINGPHASE1NCT07134842A Study Assessing if it is Safe and Possible to Treat Brain Cancer Patients With Immunotherapy Before They Receive the Standard Treatment.University College, London
- ENROLLING BY INVITATIONPHASE1NCT06896110Intrathecal Azacitidine and Nivolumab in Patients With Recurrent High-grade GliomaAndrew P. Groves
- RECRUITINGPHASE1NCT06934889Study of ABBV-637 or ABBV-155 With ERAS-801 for People With GlioblastomaMemorial Sloan Kettering Cancer Center
- RECRUITINGNCT05756985Improving Understanding of Glioblastoma Through Preservation of Biologically Active Brain TissueBaptist Health South Florida
- RECRUITINGPHASE2NCT05864534Phase 2a Immune Modulation With Ultrasound for Newly Diagnosed GlioblastomaNorthwestern University
- RECRUITINGNCT06954636Prognostic Potential of Olfactory Function in Glioblastoma: a Prospective Observational StudySied Kebir
- RECRUITINGPHASE1NCT04991870Phase I CB-NK-TGF-ßR2-/NR3C1- in rGBMM.D. Anderson Cancer Center